NEW YORK (GenomeWeb News) – Myriad Genetics will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase II clinical study for its anti-tumor drug candidate under a deal announced after the close of the market on Tuesday.

Myriad said it will conduct HRD testing for patients in a clinical study for PM1183, PharmaMar's drug candidate that induces double-stranded DNA breaks to cause cell death. The partnership, Myriad said, is the first publicly announced commercial deal covering its new HRD test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.